Novo Nordisk has notched a significant authorized win in opposition to compounding pharmacies that make copies of its diabetes and weight problems drug semaglutide, offered beneath the model names Ozempic and Wegovy.
A federal decide on Thursday dominated in opposition to a compounding commerce group’s request for a preliminary injunction that will have prevented the Meals and Drug Administration from taking motion in opposition to its members for making copies of semaglutide.
Compounding pharmacies are legally allowed to make variations of branded remedies if the medication are deemed to be in scarcity by the FDA. For the 2 years when Ozempic and Wegovy had been lately in scarcity, compounders rushed to make copies to satisfy the large demand for weight reduction remedies. However when semaglutide was in the end taken off the FDA’s scarcity record in February, the compounding commerce group, referred to as the Outsourcing Amenities Affiliation, rapidly sued the company, arguing that there have been nonetheless in reality shortages of the branded remedies.
This text is unique to STAT+ subscribers
Unlock this text — plus each day protection and evaluation of the pharma trade — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
